Physician profile
Caitlin Byrd
NPI 1164899134
$2,513.26
in general payments reported to CMS, 2019-2025
28 companies · $667 in 2025
The $667 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $626 · 2023: $507 · 2024: $332 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.05 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $345.47 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.17 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $189.22 | 2022-2024 | Xarelto |
| Abiomed | $189.21 | 2021 | |
| Edwards Lifesciences Corporation | $155.87 | 2025 | Evoque |
| Sanofi-Aventis U.S. LLC | $153.85 | 2022-2024 | |
| Amgen INC. | $152.97 | 2021-2025 | Repatha, Repatha |
| Heartflow, INC. | $147.49 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $125.40 | 2022-2023 | |
| Dompe US, INC. | $121.82 | 2023 | Oxervate |
| Alnylam Pharmaceuticals INC. | $115.81 | 2022-2025 | Onpattro |
| Novo Nordisk INC | $112.57 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Cardiovascular Systems INC. | $87.41 | 2022-2023 | Diamondback Coronary |
| Philips North America LLC | $69.93 | 2023-2025 | Ecc Solutions, Mcot, (Ck4) Mcot |
| Bayer Healthcare Pharmaceuticals INC. | $55.18 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.21 | 2021-2023 | Camzyos |
| Cmp Pharma, INC. | $39.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.31 | 2025 | |
| Altathera Pharmaceuticals LLC | $23.25 | 2022-2023 | Sotalol Hydrochloride |
| Esperion Therapeutics, INC. | $22.25 | 2021 | |
| Abbott Laboratories | $19.02 | 2025 | Mitraclip |
| Kiniksa Pharmaceuticals International, Plc | $18.66 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $17.49 | 2023 | Praluent, Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.53 | 2025 | Jardiance |
| Angiodynamics, INC. | $16.19 | 2022 | |
| Merck Sharp & Dohme LLC | $15.92 | 2022 | |
| Zoll Circulation INC | $15.80 | 2023 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Chiesi USA, INC. | $15.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.